Triangle Capital Corporation Announces Cash Dividends

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Triangle Capital Corporation Announces Cash Dividends Totaling $0.59 Per Share

RALEIGH, N.C., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Triangle Capital Corporation (NYSE: TCAP ) ("Triangle" or the "Company"), a leading provider of capital to lower middle market companies, today announced that its board of directors has declared a quarterly cash dividend of $0.54 per share. In addition to this regular quarterly dividend, Triangle will pay an extra dividend of $0.05 per share, bringing the total amount of dividends paid for the third quarter of 2014 to $0.59 per share, or $2.36 on an annualized basis. Triangle has paid 31 consecutive quarterly dividends since its initial public offering in February, 2007.

The Company's dividends will be payable as follows:

Third Quarter 2014 Dividend
Amount Per Share: $0.54
Record Date: September 10, 2014
Payment Date: September 24, 2014
     
Additional Dividend  
Amount Per Share: $0.05
Record Date: September 10, 2014
Payment Date: September 24, 2014

Dividend Reinvestment Plan

At the time of its IPO in February, 2007, Triangle adopted a dividend reinvestment plan ("DRIP") that provides for reinvestment of dividends and distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, when the Company declares a cash dividend or distribution, stockholders who have not opted out of the DRIP will have their cash dividends or distributions automatically reinvested in additional shares of the Company's common stock, rather than receiving cash. 

When the Company declares and pays dividends and distributions, it determines the allocation of the distribution between current income, accumulated income and return of capital on the basis of accounting principles generally accepted in the United States ("GAAP").  At each year end, the Company is required for tax purposes to determine the allocation based on tax accounting principles.  Due to differences between GAAP and tax accounting principles, the portion of each dividend distribution that is ordinary income, capital gain or return of capital may differ for GAAP and tax purposes.  The tax status of the Company's distributions can be found on the Investor Relations page of its website.  

About Triangle Capital Corporation

Triangle Capital Corporation ( www.TCAP.com ) invests capital in established companies in the lower middle market to fund growth, changes of control and other corporate events. Triangle offers a wide variety of investment structures with a primary focus on mezzanine financing with equity components. Triangle's investment objective is to seek attractive returns by generating current income from debt investments and capital appreciation from equity related investments. Triangle's investment philosophy is to partner with business owners, management teams and financial sponsors to provide flexible financing solutions. Triangle typically invests $5.0 million - $35.0 million per transaction in companies with annual revenues between $20.0 million and $200.0 million, and EBITDA between $3.0 million and $35.0 million.

Triangle has elected to be treated as a business development company under the Investment Company Act of 1940 ("1940 Act"). Triangle is required to comply with a series of regulatory requirements under the 1940 Act as well as applicable NYSE, federal and state laws and regulations. Triangle has elected to be treated as a regulated investment company under the Internal Revenue Code of 1986. Failure to comply with any of the laws and regulations that apply to Triangle could have a material adverse effect on Triangle and its stockholders.

Forward Looking Statements

This press release may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statements, other than statements of historical fact, are likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under the Company's control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from these estimates and projections of the future and some of these uncertainties are enumerated in Triangle's filings with the Securities and Exchange Commission. Certain factors that could cause actual results to differ materially from those contained in the forward-looking statements are included in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, each as filed with the Securities and Exchange Commission. Copies are available on the SEC's website at www.sec.gov and stockholders may receive a hard copy of the completed audited financial statements free of charge upon request to the Company at 3700 Glenwood Avenue, Suite 530, Raleigh, NC 27612. Such statements speak only as of the time when made, and the Company undertakes no obligation to update any such statement now or in the future.

Sheri Blair Colquitt Vice President, Investor Relations 919-719-4784 Steven C. Lilly Chief Financial Officer 919-719-4789

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 60

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 68

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 272

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 354

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 414

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 646

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 22

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 586

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Spring Health Launches Initiative for Mental Health Relief

Updated Category News Views 472

Spring Health's Commitment to Mental Health Support In response to the recent devastation from the wildfires, Spring Health has announced a significant initiative aimed at providing mental health resources to those in distress. The company has committed $500,000 to launch a new Wildfire Mental Health Support Program aimed at individuals and families impacted by these...

Continue Reading
Serina Therapeutics Showcases Innovations at Global Conference

Updated Category News Views 263

Serina Therapeutics Takes the Stage at Major Investment Event Serina Therapeutics, Inc., also known as Serina (NYSE American: SER), is set to make an impactful presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event unfolds in New York City, where Steve Ledger, the Chief Executive Officer of Serina, will take the spotlight at...

Continue Reading
Patrick Industries Faces Scrutiny Amid Merger Plans

Updated Category News Views 48

Cracks in the Merger Deal? Nobody likes it when a seemingly routine merger suddenly faces the magnifying glass of a class action attorney. But that's where we are with Patrick Industries (NASDAQ: PATK), folks. Juan Monteverde, the big hitter from Monteverde & Associates, is eyeing this one closely. This New York-based firm, perched in the legendary Empire State Building...

Continue Reading
Revolutionary Arab Human Pangenome: Advancing Genomic Equity

Updated Category News Views 124

Groundbreaking Achievement in Genomics PacBio, a renowned leader in sequencing technology, has made a substantial contribution to global genomics with the announcement of the first Arab human pangenome. This historic achievement is powered by their innovative HiFi long-read sequencing technology, showcasing the potential of genomic science to progress health equality...

Continue Reading
RCI Hospitality Secures Significant Legal Representation Ahead of Deadline

Updated Category News Views 226

Introduction to RCI Hospitality Holdings, Inc. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) is known for its diverse portfolio in the hospitality sector. With establishments across the country, RCI focuses on providing entertainment and dining experiences through various brands. As an investor in RCI Hospitality, it’s essential to stay informed about recent legal...

Continue Reading